Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Переносимость и степень удовлетворенности пациенток при использовании различных внутриматочных контрацептивов: результаты наблюдательной программы МИРАБЕЛЬ
Переносимость и степень удовлетворенности пациенток при использовании различных внутриматочных контрацептивов: результаты наблюдательной программы МИРАБЕЛЬ
Андреева Е.Н. Переносимость и степень удовлетворенности пациенток при использовании различных внутриматочных контрацептивов:
результаты наблюдательной программы МИРАБЕЛЬ. Гинекология. 2015; 17 (5): 37–43.
результаты наблюдательной программы МИРАБЕЛЬ. Гинекология. 2015; 17 (5): 37–43.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Высокая частота незапланированной беременности остается значительной проблемой во многих странах мира, включая Россию. Этот показатель может быть существенно снижен при применении обратимых контрацептивных методов длительного действия, к которым относятся внутриматочные контрацептивы: выделяющая левоноргестрел внутриматочная терапевтическая гормональная система и медьсодержащие внутриматочные средства. Внутриматочные контрацептивные средства высокоэффективны, характеризуются малым числом противопоказаний и побочных эффектов, экономически рентабельны при длительном применении и могут быть хорошим выбором для большинства женщин. В статье представлены результаты проспективной многоцентровой неинтервенционной сравнительной наблюдательной программы, главной целью которой явилось изучение переносимости внутриматочных контрацептивов и степени удовлетворенности пациентов результатами их применения.
Ключевые слова: контрацепция, обратимые контрацептивные методы длительного действия, внутриматочная терапевтическая гормональная система Мирена, медьсодержащие внутриматочные средства.
Key words: contraception, reversible contraceptive methods for a long-acting, intrauterine therapeutic hormonal system Mirena, copper-bearing intrauterine devices.
Ключевые слова: контрацепция, обратимые контрацептивные методы длительного действия, внутриматочная терапевтическая гормональная система Мирена, медьсодержащие внутриматочные средства.
________________________________________________
Key words: contraception, reversible contraceptive methods for a long-acting, intrauterine therapeutic hormonal system Mirena, copper-bearing intrauterine devices.
Полный текст
Список литературы
1. Mosher W, Jones J, Abma J. Nonuse of contraception among women at risk of unintended pregnancy in the United States. Contraception 2015; 92 (2): 170–6.
2. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2009. http://www.un.org/ esa/population/publications/WCU2009/Main.html.Accessed July 20, 2010
3. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills. J Midwifery Womens Health 2005; 50: 380–5.
4. Grimes DA. Forgettable contraception. Contraception 2009; 80: 497–9.
5. Peipert JF, Zhao Q, Allsworth JE et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117: 1105–13.
6. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of contraceptive use before and after an abortion: results from a nationally representative survey of women undergoing anabortion in France. Contraception 2010; 82: 337–44.
7. ACOG Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009; 114 (6): 1434–8.
8. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update 2010; 17 (1): 121–37.
9. Berenson AB, Tan A, Jacqueline M et al. Complications and continuation rates associated with 2 types of long-acting contraception. Am J Obstet Gynecol 2015; 212 (6): 761–9.
10. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 2010; 23 (29): 1–44.
11. Eeckhaut MCW, Sweeney MM, Gipson JD. Who Is Using Long-Acting Reversible Contraceptive Methods? Findings from Nine Low-Fertility Countries. Perspect Sex Reprod Health 2014; 46 (3): 149–15.
12. Прилепская В.Н., Тагиева А.В., Межевитинова Е.А. Внутриматочная контрацепция. Под. ред. В.Н.Прилепской. М., 2014; с. 40. / Prilepskaia V.N., Tagieva A.V., Mezhevitinova E.A. Vnutrimatochnaia kontratseptsiia. Pod. red. V.N.Prilepskoi. M., 2014; s. 40. [in Russian]
13. Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception. Am J Obstet Gynecol 2009; 201 (5): 456–61.
14. Leeman L. Medical barriers to effective contraception. Obstet Gynecol Clin North Am 2007; 34 (1): 19–29.
15. Dehlendorf C, Tharayil M, Anderson N et al. Counseling About IUDs: A Mixed-Methods Analysis. Perspect Sex Reprod Health 2014; 46 (3): 133–40.
16. Fleming K, Sokoloff A, Raine TR. Attitudes and beliefs about the IUD among teenagers and young women. Contraception 2010; 82: 178–82.
17. Institute of Medicine. Report Brief. Institute of Medicine of the National Academies; Jun. 2009 Initial national priorities for comparative effectiveness research. www.iom.edu/cerpriorities
18. Steinauer JE, Upadhyay UD, Sokoloff A et al. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion. Contraception 2015. pii: S0010-7824(15)00251-6
19. Winner B, Peipert JF, Zhao Q et al. Effectiveness of Long-Acting Reversible Contraception. N Engl J Med 2012; 366: 1998–2007.
20. ACOG Practice Bulletin No. 121: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2011; 118: 184–96.
21. Trussell J, Lalla AM, Doan QV et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79: 5–14.
22. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient accept ability of the intrauterine copper T-380A contraceptive device. Int J Womens Health 2010; 2: 211–20.
23. O’Neil-Callahan M, Peipert JF, Zhao Q et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol 2013; 122: 1083–91.
24. Grunloh DS, Casner T, Secura GM et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122: 1214–21.
25. Diedrich JT, Desai S, Zhao Q et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212: 50.e1–8.
26. Bahamondes MV, Monteiro I, Canteiro R et al. Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynaecol Obstet 2011; 113 (1): 50–3.
27. Madden T, McNicholas C, Zhao Q et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124 (4): 718–26.
28. Secura GM, Allsworth JE, Madden T et al. The Contraceptive CHOICE Project: reducing barriers tolong-acting reversible contraception. Am J Obstet Gynecol 2010; 203 (2): 11522–115.
29. Xu H, Wade JA, Peipert JF et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120: 21–6.
30. Макаров И.О., Боровкова Е.И. Контрацепция у пациенток с ожирением. Акушерство и гинекология. 2013; 7 (1): 36. / Makarov I.O., Borovkova E.I. Kontratseptsiia u patsientok s ozhireniem. Akusherstvo i ginekologiia. 2013; 7 (1): 36. [in Russian]
31. Gemzell-Danielsson K, Pirjo I, Heikinheimo O. Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent in sights. Exp Rev Obstet Gynecol 2013; 8 (3): 235–47.
32. Vilos GA, Marks J, Tureanu V et al. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18 (1): 75–80.
33. Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health (Lond Engl) 2013; 9 (5): 453–66.
34. Wildemeersch D. Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond – a commentary based on clinical experience. Gynecol Endocrinol 2013; 29 (6): 569–73.
35. Шестакова И.Г, Хамошина М.Б., Лебедева М.Г., Осьмакова А.А. Терапевтические возможности левоноргестрел-выделяющей внутриматочной системы у женщин в перименопаузе. Фарматека. 2015; 3: 66–70. / Shestakova I.G, Khamoshina M.B., Lebedeva M.G., Os'makova A.A. Terapevticheskie vozmozhnosti levonorgestrel-vydeliaiushchei vnutrimatochnoi sistemy u zhenshchin v perimenopauze. Farmateka. 2015; 3: 66–70. [in Russian]
36. Cleland K, Peipert JF, Westhoff C et al. Family planning as a cost-saving preventive health service. N Engl J Med 2011; 364 (18): e37.
37. Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008; 23: 1338–45.
38. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77: 1–5.
39. Cleland J. Contraception in historical and global perspective. Best Pract Res Clin Obstet Gynaecol 2009; 23 (2): 165–76.
2. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2009. http://www.un.org/ esa/population/publications/WCU2009/Main.html.Accessed July 20, 2010
3. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills. J Midwifery Womens Health 2005; 50: 380–5.
4. Grimes DA. Forgettable contraception. Contraception 2009; 80: 497–9.
5. Peipert JF, Zhao Q, Allsworth JE et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117: 1105–13.
6. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of contraceptive use before and after an abortion: results from a nationally representative survey of women undergoing anabortion in France. Contraception 2010; 82: 337–44.
7. ACOG Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009; 114 (6): 1434–8.
8. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update 2010; 17 (1): 121–37.
9. Berenson AB, Tan A, Jacqueline M et al. Complications and continuation rates associated with 2 types of long-acting contraception. Am J Obstet Gynecol 2015; 212 (6): 761–9.
10. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 2010; 23 (29): 1–44.
11. Eeckhaut MCW, Sweeney MM, Gipson JD. Who Is Using Long-Acting Reversible Contraceptive Methods? Findings from Nine Low-Fertility Countries. Perspect Sex Reprod Health 2014; 46 (3): 149–15.
12. Prilepskaia V.N., Tagieva A.V., Mezhevitinova E.A. Vnutrimatochnaia kontratseptsiia. Pod. red. V.N.Prilepskoi. M., 2014; s. 40. [in Russian]
13. Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception. Am J Obstet Gynecol 2009; 201 (5): 456–61.
14. Leeman L. Medical barriers to effective contraception. Obstet Gynecol Clin North Am 2007; 34 (1): 19–29.
15. Dehlendorf C, Tharayil M, Anderson N et al. Counseling About IUDs: A Mixed-Methods Analysis. Perspect Sex Reprod Health 2014; 46 (3): 133–40.
16. Fleming K, Sokoloff A, Raine TR. Attitudes and beliefs about the IUD among teenagers and young women. Contraception 2010; 82: 178–82.
17. Institute of Medicine. Report Brief. Institute of Medicine of the National Academies; Jun. 2009 Initial national priorities for comparative effectiveness research. www.iom.edu/cerpriorities
18. Steinauer JE, Upadhyay UD, Sokoloff A et al. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion. Contraception 2015. pii: S0010-7824(15)00251-6
19. Winner B, Peipert JF, Zhao Q et al. Effectiveness of Long-Acting Reversible Contraception. N Engl J Med 2012; 366: 1998–2007.
20. ACOG Practice Bulletin No. 121: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2011; 118: 184–96.
21. Trussell J, Lalla AM, Doan QV et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79: 5–14.
22. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient accept ability of the intrauterine copper T-380A contraceptive device. Int J Womens Health 2010; 2: 211–20.
23. O’Neil-Callahan M, Peipert JF, Zhao Q et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol 2013; 122: 1083–91.
24. Grunloh DS, Casner T, Secura GM et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122: 1214–21.
25. Diedrich JT, Desai S, Zhao Q et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212: 50.e1–8.
26. Bahamondes MV, Monteiro I, Canteiro R et al. Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynaecol Obstet 2011; 113 (1): 50–3.
27. Madden T, McNicholas C, Zhao Q et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124 (4): 718–26.
28. Secura GM, Allsworth JE, Madden T et al. The Contraceptive CHOICE Project: reducing barriers tolong-acting reversible contraception. Am J Obstet Gynecol 2010; 203 (2): 11522–115.
29. Xu H, Wade JA, Peipert JF et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120: 21–6.
30. Makarov I.O., Borovkova E.I. Kontratseptsiia u patsientok s ozhireniem. Akusherstvo i ginekologiia. 2013; 7 (1): 36. [in Russian]
31. Gemzell-Danielsson K, Pirjo I, Heikinheimo O. Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent in sights. Exp Rev Obstet Gynecol 2013; 8 (3): 235–47.
32. Vilos GA, Marks J, Tureanu V et al. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18 (1): 75–80.
33. Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health (Lond Engl) 2013; 9 (5): 453–66.
34. Wildemeersch D. Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond – a commentary based on clinical experience. Gynecol Endocrinol 2013; 29 (6): 569–73.
35. Shestakova I.G, Khamoshina M.B., Lebedeva M.G., Os'makova A.A. Terapevticheskie vozmozhnosti levonorgestrel-vydeliaiushchei vnutrimatochnoi sistemy u zhenshchin v perimenopauze. Farmateka. 2015; 3: 66–70. [in Russian]
36. Cleland K, Peipert JF, Westhoff C et al. Family planning as a cost-saving preventive health service. N Engl J Med 2011; 364 (18): e37.
37. Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008; 23: 1338–45.
38. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77: 1–5.
39. Cleland J. Contraception in historical and global perspective. Best Pract Res Clin Obstet Gynaecol 2009; 23 (2): 165–76.
2. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2009. http://www.un.org/ esa/population/publications/WCU2009/Main.html.Accessed July 20, 2010
3. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills. J Midwifery Womens Health 2005; 50: 380–5.
4. Grimes DA. Forgettable contraception. Contraception 2009; 80: 497–9.
5. Peipert JF, Zhao Q, Allsworth JE et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117: 1105–13.
6. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of contraceptive use before and after an abortion: results from a nationally representative survey of women undergoing anabortion in France. Contraception 2010; 82: 337–44.
7. ACOG Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009; 114 (6): 1434–8.
8. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update 2010; 17 (1): 121–37.
9. Berenson AB, Tan A, Jacqueline M et al. Complications and continuation rates associated with 2 types of long-acting contraception. Am J Obstet Gynecol 2015; 212 (6): 761–9.
10. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 2010; 23 (29): 1–44.
11. Eeckhaut MCW, Sweeney MM, Gipson JD. Who Is Using Long-Acting Reversible Contraceptive Methods? Findings from Nine Low-Fertility Countries. Perspect Sex Reprod Health 2014; 46 (3): 149–15.
12. Прилепская В.Н., Тагиева А.В., Межевитинова Е.А. Внутриматочная контрацепция. Под. ред. В.Н.Прилепской. М., 2014; с. 40. / Prilepskaia V.N., Tagieva A.V., Mezhevitinova E.A. Vnutrimatochnaia kontratseptsiia. Pod. red. V.N.Prilepskoi. M., 2014; s. 40. [in Russian]
13. Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception. Am J Obstet Gynecol 2009; 201 (5): 456–61.
14. Leeman L. Medical barriers to effective contraception. Obstet Gynecol Clin North Am 2007; 34 (1): 19–29.
15. Dehlendorf C, Tharayil M, Anderson N et al. Counseling About IUDs: A Mixed-Methods Analysis. Perspect Sex Reprod Health 2014; 46 (3): 133–40.
16. Fleming K, Sokoloff A, Raine TR. Attitudes and beliefs about the IUD among teenagers and young women. Contraception 2010; 82: 178–82.
17. Institute of Medicine. Report Brief. Institute of Medicine of the National Academies; Jun. 2009 Initial national priorities for comparative effectiveness research. www.iom.edu/cerpriorities
18. Steinauer JE, Upadhyay UD, Sokoloff A et al. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion. Contraception 2015. pii: S0010-7824(15)00251-6
19. Winner B, Peipert JF, Zhao Q et al. Effectiveness of Long-Acting Reversible Contraception. N Engl J Med 2012; 366: 1998–2007.
20. ACOG Practice Bulletin No. 121: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2011; 118: 184–96.
21. Trussell J, Lalla AM, Doan QV et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79: 5–14.
22. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient accept ability of the intrauterine copper T-380A contraceptive device. Int J Womens Health 2010; 2: 211–20.
23. O’Neil-Callahan M, Peipert JF, Zhao Q et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol 2013; 122: 1083–91.
24. Grunloh DS, Casner T, Secura GM et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122: 1214–21.
25. Diedrich JT, Desai S, Zhao Q et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212: 50.e1–8.
26. Bahamondes MV, Monteiro I, Canteiro R et al. Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynaecol Obstet 2011; 113 (1): 50–3.
27. Madden T, McNicholas C, Zhao Q et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124 (4): 718–26.
28. Secura GM, Allsworth JE, Madden T et al. The Contraceptive CHOICE Project: reducing barriers tolong-acting reversible contraception. Am J Obstet Gynecol 2010; 203 (2): 11522–115.
29. Xu H, Wade JA, Peipert JF et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120: 21–6.
30. Макаров И.О., Боровкова Е.И. Контрацепция у пациенток с ожирением. Акушерство и гинекология. 2013; 7 (1): 36. / Makarov I.O., Borovkova E.I. Kontratseptsiia u patsientok s ozhireniem. Akusherstvo i ginekologiia. 2013; 7 (1): 36. [in Russian]
31. Gemzell-Danielsson K, Pirjo I, Heikinheimo O. Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent in sights. Exp Rev Obstet Gynecol 2013; 8 (3): 235–47.
32. Vilos GA, Marks J, Tureanu V et al. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18 (1): 75–80.
33. Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health (Lond Engl) 2013; 9 (5): 453–66.
34. Wildemeersch D. Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond – a commentary based on clinical experience. Gynecol Endocrinol 2013; 29 (6): 569–73.
35. Шестакова И.Г, Хамошина М.Б., Лебедева М.Г., Осьмакова А.А. Терапевтические возможности левоноргестрел-выделяющей внутриматочной системы у женщин в перименопаузе. Фарматека. 2015; 3: 66–70. / Shestakova I.G, Khamoshina M.B., Lebedeva M.G., Os'makova A.A. Terapevticheskie vozmozhnosti levonorgestrel-vydeliaiushchei vnutrimatochnoi sistemy u zhenshchin v perimenopauze. Farmateka. 2015; 3: 66–70. [in Russian]
36. Cleland K, Peipert JF, Westhoff C et al. Family planning as a cost-saving preventive health service. N Engl J Med 2011; 364 (18): e37.
37. Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008; 23: 1338–45.
38. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77: 1–5.
39. Cleland J. Contraception in historical and global perspective. Best Pract Res Clin Obstet Gynaecol 2009; 23 (2): 165–76.
________________________________________________
2. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2009. http://www.un.org/ esa/population/publications/WCU2009/Main.html.Accessed July 20, 2010
3. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills. J Midwifery Womens Health 2005; 50: 380–5.
4. Grimes DA. Forgettable contraception. Contraception 2009; 80: 497–9.
5. Peipert JF, Zhao Q, Allsworth JE et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117: 1105–13.
6. Moreau C, Trussell J, Desfreres J, Bajos N. Patterns of contraceptive use before and after an abortion: results from a nationally representative survey of women undergoing anabortion in France. Contraception 2010; 82: 337–44.
7. ACOG Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009; 114 (6): 1434–8.
8. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update 2010; 17 (1): 121–37.
9. Berenson AB, Tan A, Jacqueline M et al. Complications and continuation rates associated with 2 types of long-acting contraception. Am J Obstet Gynecol 2015; 212 (6): 761–9.
10. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat 2010; 23 (29): 1–44.
11. Eeckhaut MCW, Sweeney MM, Gipson JD. Who Is Using Long-Acting Reversible Contraceptive Methods? Findings from Nine Low-Fertility Countries. Perspect Sex Reprod Health 2014; 46 (3): 149–15.
12. Prilepskaia V.N., Tagieva A.V., Mezhevitinova E.A. Vnutrimatochnaia kontratseptsiia. Pod. red. V.N.Prilepskoi. M., 2014; s. 40. [in Russian]
13. Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception. Am J Obstet Gynecol 2009; 201 (5): 456–61.
14. Leeman L. Medical barriers to effective contraception. Obstet Gynecol Clin North Am 2007; 34 (1): 19–29.
15. Dehlendorf C, Tharayil M, Anderson N et al. Counseling About IUDs: A Mixed-Methods Analysis. Perspect Sex Reprod Health 2014; 46 (3): 133–40.
16. Fleming K, Sokoloff A, Raine TR. Attitudes and beliefs about the IUD among teenagers and young women. Contraception 2010; 82: 178–82.
17. Institute of Medicine. Report Brief. Institute of Medicine of the National Academies; Jun. 2009 Initial national priorities for comparative effectiveness research. www.iom.edu/cerpriorities
18. Steinauer JE, Upadhyay UD, Sokoloff A et al. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion. Contraception 2015. pii: S0010-7824(15)00251-6
19. Winner B, Peipert JF, Zhao Q et al. Effectiveness of Long-Acting Reversible Contraception. N Engl J Med 2012; 366: 1998–2007.
20. ACOG Practice Bulletin No. 121: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2011; 118: 184–96.
21. Trussell J, Lalla AM, Doan QV et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79: 5–14.
22. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient accept ability of the intrauterine copper T-380A contraceptive device. Int J Womens Health 2010; 2: 211–20.
23. O’Neil-Callahan M, Peipert JF, Zhao Q et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol 2013; 122: 1083–91.
24. Grunloh DS, Casner T, Secura GM et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013; 122: 1214–21.
25. Diedrich JT, Desai S, Zhao Q et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212: 50.e1–8.
26. Bahamondes MV, Monteiro I, Canteiro R et al. Length of the endometrial cavity and intrauterine contraceptive device expulsion. Int J Gynaecol Obstet 2011; 113 (1): 50–3.
27. Madden T, McNicholas C, Zhao Q et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124 (4): 718–26.
28. Secura GM, Allsworth JE, Madden T et al. The Contraceptive CHOICE Project: reducing barriers tolong-acting reversible contraception. Am J Obstet Gynecol 2010; 203 (2): 11522–115.
29. Xu H, Wade JA, Peipert JF et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120: 21–6.
30. Makarov I.O., Borovkova E.I. Kontratseptsiia u patsientok s ozhireniem. Akusherstvo i ginekologiia. 2013; 7 (1): 36. [in Russian]
31. Gemzell-Danielsson K, Pirjo I, Heikinheimo O. Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent in sights. Exp Rev Obstet Gynecol 2013; 8 (3): 235–47.
32. Vilos GA, Marks J, Tureanu V et al. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18 (1): 75–80.
33. Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health (Lond Engl) 2013; 9 (5): 453–66.
34. Wildemeersch D. Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond – a commentary based on clinical experience. Gynecol Endocrinol 2013; 29 (6): 569–73.
35. Shestakova I.G, Khamoshina M.B., Lebedeva M.G., Os'makova A.A. Terapevticheskie vozmozhnosti levonorgestrel-vydeliaiushchei vnutrimatochnoi sistemy u zhenshchin v perimenopauze. Farmateka. 2015; 3: 66–70. [in Russian]
36. Cleland K, Peipert JF, Westhoff C et al. Family planning as a cost-saving preventive health service. N Engl J Med 2011; 364 (18): e37.
37. Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008; 23: 1338–45.
38. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77: 1–5.
39. Cleland J. Contraception in historical and global perspective. Best Pract Res Clin Obstet Gynaecol 2009; 23 (2): 165–76.
Авторы
Е.Н.Андреева*
ФГБУ Эндокринологический научный центр Минздрава России. 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11
*gynec@endocrincentr.ru
Endocrinology research center of the Ministry of Health of the Russian Federation. 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11
*gynec@endocrincentr.ru
ФГБУ Эндокринологический научный центр Минздрава России. 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11
*gynec@endocrincentr.ru
________________________________________________
Endocrinology research center of the Ministry of Health of the Russian Federation. 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11
*gynec@endocrincentr.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.